STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-253)	ILOFOTASE ALFA
PRONUNCIATION	eye loe' foe tase al' fa
THERAPEUTIC CLAIM	Treatment of sepsis-associated acute kidney injury

CHEMICAL NAMES

1. 1-365-Intestinal alkaline phosphatase [279-leucine,328-valine] (human) fusion protein with 366-430-placental alkaline phosphatase (human) fusion protein with 431-484-intestinal alkaline phosphatase [478-leucine] (human), dimer (Source: CAS)

2. human intestinal-type alkaline phosphatase (IAP) variant (H279>L, L328>V, P478>L), engineered by substituting its crown domain (366-430) with the human placental-type alkaline phosphatase (placental alkaline phosphatase 1, PLAP-1) crown domain (364-428, 366-430 in the current sequence), C-terminal linked glycosylphosphatidylinositol anchor removed, dimer, glycosylated, produced in Chinese hamster ovary (CHO) cells; human intestinal-type alkaline phosphatase (ALPI, intestinal alkaline phosphatase, IAP) variant [H279>L, L328>V, P478>L] (1-484) with its crown domain (65-peptide 366-430) being replaced by the human placental-type alkaline phosphatase (ALPP, alkaline phosphatase Regan isozyme, placental alkaline phosphatase 1, PLAP-1) crown domain (65-peptide 364-428) (366-430), dimer (481-481')-disulfide, without glycosylphosphatidylinositol (GPI) anchors at Asp-484 and Asp-484' (secretable, soluble enzyme), produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source: WHO pINN list 124)

STRUCTURAL FORMULA

Sequence (X, X')

```
VIPAEEENPA  FWNRQAAEAL  DAAKKLQPIQ  KVAKNLILFL  GDGLGVPTVT  50
ATRILKGQKN  GKLGPETPLA  MDRFPYLALS  KTYNVDRQVP  DSAATATAYL  100
CGVKANFQTI  GLSAAARFNQ  CNTTRGNEVI  SVMNRAKQAG  KSVGVVTTTR  150
VQHASPAGTY  AHTVNRNWYS  DADMPASARQ  EGCQDIATQL  ISNMDIDVIL  200
GGGRKYMFPM  GTPDPEYPAD  ASQNGIRLDG  KNLVQEWLAK  HQGAWYVWNR  250
TELMQASLDQ  SVTHLMGLFE  PGDTKYEILR  DPTLDPSLME  MTEAALRLLS  300
RNPRGFYLFV  EGGRIDHGHH  EGVAYQAVTE  AVMFDDAIER  AGQLTSEEDT  350
LTLVTADHSH  VFSFGGYPLR  GSSIFGLAPG  KARDRKAYTV  LLYGNGPGYV  400
LKDGARPDVT  ESESGSPEYR  QQSAVPLDEE  THGGEDVAVF  ARGPQAHLVH  450
GVQEQSFVAH  VMAFAACLEP  YTACDLALPA  CTTD                    484
```

Disulfide bridges

121-183 121'-183' 467-484 467'-484' 481-481'

Glycosylation sites (N)

122 122' 249 249'

MOLECULAR FORMULA $C_{4634}H_{7226}N_{1300}O_{1429}S_{36}$

MOLECULAR WEIGHT 105.1 kDa

TRADEMARK	None as yet
SPONSOR	AM-Pharma B.V.
CODE DESIGNATIONS	human recAP
CAS REGISTRY NUMBER	2387636-92-0
UNII	9N4Y2R43OM
WHO NUMBER	11641

gbk